Luye Pharma Group Limited operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Luye Pharma Group Limited with three other
pharmaceutical manufacturers in Asia:
ChangChun High New Technology Industries
sales of 2.87 billion Chinese Renmimbi [US$446.46 million]
of which 81%
Kimia Farma (Persero) Tbk PT
(5.81 trillion Indonesian Rupiahs [US$435.86 million]
of which 52%
was Retail), and
Hunan ER-KANG Pharmaceutical Co Ltd
based in China
(2.96 billion Chinese Renmimbi [US$459.97 million]
of which 92%
was Manufacture of Medicines).
Luye Pharma Group Limited reported sales of 605.73 million Singapore Dollars (US$458.54 million)
December of 2016.
increase of 7.8%
versus 2015, when the company's sales were 561.71 million Singapore Dollars.
Despite this increase, sales are still
below the level achieved in 2014, when Luye Pharma Group Limited
reported sales of 649.30 million Singapore Dollars.
Sales of Other saw an increase
that was more than double the company's growth rate: sales were up
71.4% in 2016, from
17.14 million Singapore Dollars to 29.37 million Singapore Dollars.
Luye Pharma Group Limited also saw significant increases in sales in
Alimentary Tract and Metabolism Drugs (up 12.2% to 115.11 million Singapore Dollars)
Not all segments of Luye Pharma Group Limited experienced an increase in sales in 2016:
sales of Cardio-Vascular System Drugs fell 0.6% to 135.33 million Singapore Dollars.